A randomized phase 2/3 study of naptumomab estafenatox + IFN-α vs IFN-α in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis
Authors
Hawkins, Robert EGore, M
Shparyk, Y
Bondar, V
Gladkov, O
Ganev, T
Harza, M
Polenkov, S
Bondarenko, I
Karlov, P
Karyakin, O
Khasanov, R
Hedlund, G
Forsberg, G
Nordle, O
Eisen, T
Affiliation
Medical Oncology, Christie CRC Research CentreIssue Date
2016-02-05
Metadata
Show full item recordAbstract
To prospectively determine the efficacy of naptumomab estafenatox (Nap) + interferon α (IFN) versus IFN in metastatic renal cell carcinoma (RCC).Citation
A randomized phase 2/3 study of naptumomab estafenatox + IFN-α vs IFN-α in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis. 2016: Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-15-0580PubMed ID
26851187Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-15-0580
Scopus Count
Collections
Related articles
- Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.
- Authors: Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins RE
- Issue date: 2015 Feb 28
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
- Authors: Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ
- Issue date: 2010 May 1
- Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
- Authors: Ravasio R, Ortega C, Sabbatini R, Porta C
- Issue date: 2011
- Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
- Authors: Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM
- Issue date: 2009 Mar 10
- Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
- Authors: Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ
- Issue date: 2008 Nov 20